The ability of herpes simplex virus (HSV)-specific, cytotoxic T 
The ability of herpes simplex virus (HSV)-specific, cytotoxic T lymphocytes to mediate recovery of mice lethally infected with HSV was examined. Adoptive transfer of splenocytes from mice that had been primed in vivo with HSV and restimulated with HSV in vitro protected lethally infected normal and cyclophosphamide-immunosuppressed mice from death. In contrast, equal numbers of normal splenocytes or immune splenocytes cultured without antigen failed to mediate recovery. Recovery was also transferred by noncultured, primary immune splenocytes, although the protective efficacy of these cells was 10-fold less than when immune splenocytes restimulated in vitro were used. Treatment of the cells with anti-Thy 1 or anti-Lyt 2.1 plus complement before adoptive transfer abrogated recovery. No decrease in protection was seen when in vitro-restimulated splenocytes were treated with anti-Lyt 1.1 plus complement. Splenocytes expression natural killer activity also failed to effect recovery.The administration of hyperimmune anti-HSV antibody to normal, immunocompetent mice resulted in recovery, whereas no significant protection of immunosuppressed mice by anti-HSV was observed. When antibody was given concurrently with cultured immune splenocytes, the percentage of mice that recovered from infection was greater than that seen with either antibody or cultured immune splenocytes alone. These experiments demonstrate that Lyt 2-positive cells with cytotoxic activity generated by in vitro immunization can mediate recovery from lethal HSV infection, whereas, under the conditions chosen, Lyt 1-positive cells were unable to mediate recovery.
The immunological nature of in vivo resistance mechanisms to herpes simplex virus (HSV) remains to be clarified as to the respective importance of the many components of adaptive immunity that can be measured and shown specifically reactive to HSV antigens in vitro. Probably multiple mechanisms can operate, this accounting in part for opposing viewpoints on the relative protective role of one or another component. Furthermore, in discussing the protective function of various immune mechanisms, it is important to specify which stage of virus-host interaction is involved. Thus, there seems little doubt that antibody, prepared against either the whole virus (13, 22, 23, 26) or several of the glycoproteins of the envelope (2, 5) , can protect against primary infection providing that the antibodies are present in sufficient concentrations at the site of challenge. Such antibody probably prevents attachment of virus to target cells, although the exact mechanism in vivo has not been elucidated. Usually protection against primary infections is accomplished by natural resistance mechanisms rather than by adaptive immunity. Such natural resistance mechanisms against HSV include natural killer cells (1, 7, 27) , interferon (7, 9, 27) , and macrophages (8, 10, 14, 15, 25, 27, 28) . Worthington et al. (26) supported the role of antibody in recovery from HSV infection and suggested that any protection mediated by adoptive transfer of immune cells could be attributed to the production of antibody by the transferred cell population. This is probably an oversimplification, since several observations support a role for T cells in protection and recovery. Nash et al. (20) have clearly shown protection is mediated by T cells, but they favor a principal role for the I region-restricted Lyt 1-positive, Lyt 2-negative (Lyt 1+2-) delayed-type hypersensitivity-mediating T cell, rather than T cell subsets that are cytotoxic. A principal role for Lyt 1+2-T cells was also observed by Nagafuchi et al. (18) , but this was in a model of protection rather than recovery. The purpose of our research was to investigate the role of cytotoxic T 
MATERIALS AND METHODS
Virus. An oral isolate of HSV type 1 (HSV-1) (BK strain) was used to infect mice in adoptive transfer experiments. HSV-1 KOS was used to immunize mice for the production of immune spleen cells. Each strain was grown in HEp-2 cells by infecting at low multiplicity and harvesting cell-associated virus as previously described (3) .
Mouse immunization and preparation of splenocytes. C3H/HeJ mice were obtained from the University of Tennessee Medical Research Center. Mice 6 to 9 weeks of age were used as recipients in the adoptive transfer studies. Animals serving as cell donors were infected intraperitoneally (i.p.) with 0.1-ml inocula containing 106 PFU of infectious HSV-1 KOS. At least 4 weeks after infection, the mice were killed by cervical dislocation, and their spleens were removed aseptically for preparation of single-cell suspensions as described elsewhere (12) . In those cases where transfer of restimulated cells was desired, spleen cells were adjusted to 2 x 106/ml in RPMI 1640 containing 10% fetal calf serum, 2 mM glutamine, penicillin (100 U/mi), streptomycin (100,ug/ml), and 5 x 10-5 M 2-mercaptoethanol and added to plastic tissue culture plates at a density of 106/cm2 of surface area. UV lightinactivated virus (107 PFU) then was added, and the spleen cell cultures were incubated in a humidified atmosphere of 5% CO2 at 37°C. After 5 days, the cells were harvested and washed in medium, and the cell density was adjusted to the desired concentration.
Detection of B lymphocytes. B lymphocytes were detected with fluorescein-conjugated anti-mouse immunoglobulins (Cappel Laboratories, West Chester, Pa.). Briefly, the 5-day restimulated immune spleen cells were pelleted, and 0.1 ml of fluoresceinated antiserum (diluted 1:30) was added. After 30 min at 4°C, the cells were washed twice in phosphate-buffered saline and suspended in a mixture of 1 Immunosuppressed mice which were subsequently infected with HSV-1 were given spleen cells obtained from mice immunized 6 weeks previously with infectious HSV-1 ( Table 2) . Recovery and subsequent protection from death were achieved with the transfer of 5 x 107 noncultured immune spleen cells, whereas 5 x 107 nonimmune cells or less than 5 x 107 noncultured immune spleen cells failed to transfer significant protection. Table 3 shows that, in contrast to that seen with imunocompetent mice, no significant pro- c The values shown represent means of quaduplicate cultures run at effector cell target cell ratios of 25:1. The standard errors for the 4-h assays were always below 4%. The L targets were L929 cells which were infected with HSV-1 (L-HSV) or uninfected (L). The A31 targets were BALB/c 3T3 clone A31 which were infected with HSV-1 (A31-HSV).
d Spleen cells from C3H/HeJ mice primed 4 to 6 weeks previously with HSV-1 were cultured for 5 days with UV-inactivated HSV-1.
e Spleen cells from nonimmune C3H/HeJ mice infected intravenously 2 days previously with 107 PFU of HSV-1. cells, the number of mice that recovered from infection was greater than that seen with either antibody or cultured immune spleen cells alone ( Table 7) . Inoculation of 2 x 10 cultured normal cells plus antibody failed to result in recovery.
DISCUSSION
The essential aim of our studies was to define the role of CTL in recovery from HSV-1 infection in mice. To achieve this, normal or immunosuppressed mice were infected with virus, and the effect of adoptive transfers of various cell populations was recorded. We have shown that spleen cells taken from mice previously infected with HSV (HSV-immune mice) and immunized in vitro with inactivated virus express potent H-2-restricted, HSV-specific, cytotoxic activity (12) . Such cells conferred protection, as judged by survival from an otherwise lethal infection, to both normal and cyclophosphamide-immunosuppressed mice. Protection was not afforded by similar numbers of normal splenocytes, immune splenocytes cultured in the absence of antigen, or immune splenocytes before in vitro restimulation. However, transfer of the last cell population resulted in recovery when given at higher cell numbers. On the average, the protective efficacy of immune, noncultured splenocytes was 10-fold less than that of in vitro-immunized immune splenocytes. These data strongly imply that CTL were responsible for the protection, although the case for CTL would have been stronger had their effectiveness in comparison to the other cell transfers been even greater. Several factors should be considered which could explain why greater differences were not observed. First, to exert protection the immune (27) . Ablation of protective effects by anti-T cell sera also argues strongly against the suggestion by Worthington et al. (26) that any protective effect observed with adoptive cell transfers can be attributed to antibody production by the transferred cells. It also rules out protection due to the transfer of helper T cells that permits antibody production by the donor or recipient B cells. It is of interest to note that the adoptive protective effects of spleen cells from animals recently activated with virus is affected by anti-Lyt 1 serum, not by Lyt 2 serum, an observation taken to argue for the role of a helper cell-or delayed-type hypersensitivity-mediating T cell, both of which express the Lyt 2 phenotype (4, 18) . This shows that other cell types can also mediate immunity, but, in addition, it should be noted that CTL precursors are Lyt 1+2 cells and so also would also be removed by the anti-Lyt 1 serum treatment (24) .
Our observation that CTL can confer to mice the ability to recover from HSV infection does not mean that these cells mediate their protective effects in vivo by expressing cytotoxicity. A study with a cloned cytotoxic T cell line demonstrated the production of interferon upon exposure to antigen (17) . Such interferon could mediate recovery either directly by protecting uninfected cells or indirectly by NK cell activation and recycling (1, 27 
